XTL Biopharmaceuticals's basic earnings per share (Basic EPS) for the
three
months ended in Sep. 2023 was $-0.07.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.40.
XTL Biopharmaceuticals's EPS without NRI for the
three
months ended in Sep. 2023 was $-0.06.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was -0.14.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
XTL Biopharmaceuticals EPS (Basic) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
XTL Biopharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
XTL Biopharmaceuticals EPS (Basic) Related Terms
Thank you for viewing the detailed overview of XTL Biopharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
XTL Biopharmaceuticals (XTL Biopharmaceuticals) Business Description
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTLB has been successfully added to your 